Hierro sacarosa intravenoso en el paciente con enfermedad renal crónica

1. Elena Donado ¹
2. Marta Aguasca ¹
3. Julen Ocharan-Corcuera ²
4. Iñaki Minguela ²
5. Isabel Gimeno ²
6. Alejandro Chena ²
7. Ramón Ruiz-de-Gauna ²

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/S1886-2845(07)71347-4 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Diálisis y trasplante: publicación oficial de la Sociedad Española de Diálisis y Trasplante

Abstract

We review the treatment of renal anemia with intravenous iron sucrose in predialysis, hemodialysis and peritoneal dialysis patients. The available evidence shows that intravenous iron sucrose is a highly effective treatment for iron-deficiency anemia in patients with renal disease Moreover, intravenous iron sucrose is a cost-effective treatment because it reduces the required dosage of erythropoiesis-stimulating agents. Intravenous iron sucrose is safe and well-tolerated and, therefore, represents a good choice for the treatment and prevention of iron-deficiency anemia.

Data source: Dialnet